Drugs / gp140
gp140
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02304185 | Dec 2014 → Apr 2016 | — | Crucell Holland BV | Completed | No outcome recorded |
| Phase 1 | NCT01418235 | Dec 2011 → Oct 2013 | — | HIV Vaccine Trials Network | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02304185 ↗ |
| Known as | Glycoprotein 140 | “Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.” NCT02304185 ↗ |
| Known as | Novartis Clade C gp140TV1ΔV2 | “Novartis Clade C gp140TV1ΔV2 with MF59 adjuvant” NCT01418235 ↗ |
| Known as | Novartis V2-deleted subtype C gp140 | “Novartis V2-deleted subtype C gp140 (100 mcg) with MF59 adjuvant” PMID 27583368 ↗ Sep 2016 |
| Modality | Vaccine | “gp140 vaccine” NCT02304185 ↗ |